Thrive Earlier Detection Overview

  • Founded
  • 2019
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 100
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $2.19B
Latest Deal Amount

Thrive Earlier Detection General Information

Description

Developer of a liquid biopsy test designed to integrate earlier cancer detection into routine medical care. The company's blood-based test combines analysis of a highly targeted set of DNA and protein measurements from blood to detect cancer and is integrated with real-world data and machine learning to offer result interpretation, follow-up testing, confirmed cancer diagnosis and facilitation into oncology care, enabling physicians to detect multiple types of cancer at earlier stages.

Contact Information

Website
www.thrivedetect.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Parent Company
Exact Sciences
Primary Office
  • 38 Sidney Street
  • Cambridge, MA 02139
  • United States
+1 (760) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Thrive Earlier Detection Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 05-Jan-2021 $2.19B 00000 00.000 Completed Generating Revenue
3. Later Stage VC (Series B) 24-Jul-2020 00000 00000 00000 Completed Generating Revenue
2. Later Stage VC (Series A) 30-May-2019 $110M $110M 00000 Completed Startup
1. Accelerator/Incubator 28-May-2019 Completed Startup
To view Thrive Earlier Detection’s complete valuation and funding history, request access »

Thrive Earlier Detection Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B 000,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A 000,000,000 00.000000 00 00 00 00 00 00.000
Junior A-1 1,757,406 $0.001000 8% $3.41 $3.41 1x $3.41 0.64%
Junior A 3,451,468 $0.001000 8% $0.87 $0.87 1x $0.87 1.27%
To view Thrive Earlier Detection’s complete cap table history, request access »

Thrive Earlier Detection Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a liquid biopsy test designed to integrate earlier cancer detection into routine medical care. The company'
Biotechnology
Cambridge, MA
100 As of 2020
00000
0.000 0000-00-00
000000&0 00000

00000000

o consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat
0000000000000
Newark, CA
000 As of 0000
000.00
0000 0000-00-00
000000&0 000.00

00000000

dunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco la
0000000000000
Epalinges, Switzerland
0 As of 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Thrive Earlier Detection Competitors (29)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Advanced Cell Diagnostics Formerly VC-backed Newark, CA 000 000.00 000000&0 000.00
000000000 Corporation Epalinges, Switzerland 0
0000000 0000 Venture Capital-Backed Sunnyvale, CA 00 0000 00000000000 0000
000000000 00000000 Venture Capital-Backed San Diego, CA 0 000.00 000000000 000.00
0000000 0000000000 Venture Capital-Backed Beverly, MA 00 000.00 000000 0 000.00
You’re viewing 5 of 29 competitors. Get the full list »

Thrive Earlier Detection Patents

  • 2

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

Thrive Earlier Detection Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210010063-A1 Barcoded molecular standards Pending 15-Feb-2018 0000000000
EP-3752636-A1 Barcoded molecular standards Pending 15-Feb-2018 0000000000

Thrive Earlier Detection Executive Team (14)

Name Title Board Seat Contact Info
Isaac Kinde Ph.D Co-founder & Head of Research And Innovation
Nickolas Papadopoulos Ph.D Co-Founder & Board Member
Bert Vogelstein MD Co-Founder
David Daly Chief Executive Officer & Board Member
Christoph Lengauer Ph.D Co-Founder, Board Member & Chief Innovation Officer
You’re viewing 5 of 14 executive team members. Get the full list »

Thrive Earlier Detection Board Members (9)

Name Representing Role Since
Christoph Lengauer Ph.D Self Co-Founder, Board Member & Chief Innovation Officer 000 0000
David Daly Self Chief Executive Officer & Board Member 000 0000
Nickolas Papadopoulos Ph.D Thrive Earlier Detection Co-Founder & Board Member 000 0000
You’re viewing 3 of 9 board members. Get the full list »

Thrive Earlier Detection Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Thrive Earlier Detection Former Investors (20)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Bain Capital Life Sciences Corporate Venture Capital Minority 000 0000 000000 0
Biomatics Capital Venture Capital Minority 000 0000 000000 0
Blue Venture Fund Corporate Venture Capital Minority 000 0000 000000 0
Brown Advisory Asset Manager Minority 000 0000 000000 0
Casdin Capital Hedge Fund Minority 000 0000 000000 0
You’re viewing 5 of 20 investors. Get the full list »

Ready to get started?

Request a free trial